A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
A phase 3 trial testing Precemtabart tocentecan in colorectal cancer, now recruiting.
Overview
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) is a phase 3 interventional study registered as NCT07549412, led by EMD Serono Research & Development Institute with Merck KGaA, Darmstadt, Germany, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03). Planned enrolment is 1020 participants (estimated). The study started in 2026-05-06 and primary completion is expected in 2029-10-16. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialPerformance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Shares Colorectal cancer and the tag ctgov-ingest.